Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Rhea-AI Summary
Lipocine (NASDAQ: LPCN) has announced that two abstracts for their drug candidate LPCN 2101, being developed for epilepsy treatment, have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting in Atlanta, Georgia, December 5-9.
The presentations will focus on the oral toxicokinetics and clinical pharmacokinetics of LPCN 2101, a GABA A receptor modulating neuroactive steroid. The first presentation is scheduled for December 7, and the second for December 8, 2025. The abstracts are currently under embargo until November 24, 2025.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LPCN gained 2.65%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AES 2025 Annual Meeting: December 5-9, 2025
| |
Title: | Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating |
Author: | Joshua C. Weavil, Jonathan Ogle, Min-Jee Goh, Joel Frank, Samuel Akapo, |
Date: | Sunday, December 7, 12:00 PM – 2:00 PM |
Abstract Number: | 2.331 |
Title: | Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA |
Author: | Min-Jee Goh, Jonathan Ogle, Joshua C. Weavil, Joel Frank, Samuel Akapo, |
Date: | Monday, December 8, 2025, 12:00 PM – 1:45 PM |
Abstract Number: | 3.354 |
Abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-lpcn-2101-abstracts-accepted-for-presentation-at-aes-2025-302538110.html
SOURCE Lipocine Inc.
FAQ
When and where will Lipocine (LPCN) present its LPCN 2101 abstracts at AES 2025?
What is LPCN 2101 being developed for by Lipocine?
What topics will be covered in Lipocine's AES 2025 presentations?
When will the Lipocine (LPCN) AES 2025 abstracts become publicly available?
